Biomanufacturing Strategies - Market drivers, build-vs-buy decisions and opportunities in contract relationship management

The contract biomanufacturing market achieved a value of $2.5bn in 2006, with growth expected to continue at an annual rate of 0- 5% until at least 20. The proportion of biologics in new drug approvals has risen by over 30% during the last decade, and with the current pipeline containing more than 500 protein and 50 peptide developmental drugs, this trend is set to continue. The commercial success of over 350 approved biologics has prompted the biotechnology industry to accelerate discoveries in further protein-based therapeutics, placing greater emphasis upon the importance of biomanufacturing. Many biotechnology companies are faced with limited resources, and as large-scale manufacturing continues to intensify, deciding whether it should be internalised or outsourced to partners or CMO’s is increasingly crucial in the development of a biotech firm. Biomanufacturing Strategies is a new report published by Business Insights that examines the future direction of biomanufacturing through a detailed analysis of market drivers, restraints and trends. The production strategies and capacities of leading biopharma companies are assessed, and growth forecasts for microbial fermentations and mammalian cell culture are provided. This report will also detail the tactical balance required between a firm’s potential manufacturing capability and overall corporate strategy, in addition to profiling other key factors that bear crucial importance to the ‘build vs buy’ decision. Use this report to identify the key criteria involved in CMO selection, compare the expansion strategies and capacity shares of leading players and analyse the growth drivers shaping the future of biomanufacturing.

September 2007 Pages 182 Format PDF
Table of Contents
Price: $2,875.00 / GBP1,437.50